Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Epigenetic control of anti-tumor immunity in squamous cell carcinoma

EF 2021-22

Résumé
Head and neck squamous cell carcinoma, the sixth most common cancer worldwide, is a lethal malignancy. Immunotherapy is a new cancer treatment that aims to stimulate our immune system to fight such refractory cancers more effectively. Unfortunately, only less than 20% of head and neck cancer patients respond to this treatment. The majority of head and neck cancers are immune "cold" tumors because they lack tumor infiltrating immune cells that can kill cancer cells. These immune "cold" tumors are resistant to immunotherapy and are associated with poor prognosis. Moreover, there are no established biomarkers to discern which patients are more likely to benefit from immunotherapies. To reduce mortality of head and neck cancer patients, we therefore need to understand how cancer cells become resistant to immunotherapies and to develop biomarkers to predict patients' response to such therapies. This would allow us to develop better combinatorial strategies to improve the efficacy of cancer immune therapies. Recently, our laboratory has discovered a previously unknown mechanism by which such cancers avoid immune cell attack and develop resistance to immunotherapy. My project aims to understand how this mechanism drives tumors to develop therapeutic resistance. Understanding this will allow us to reverse this tumor survival mechanism and develop combinatorial therapies to improve the efficacy of the current immune therapies. Finally, I also aim to identify biomarkers to predict patients' response to immunotherapies. Findings from this research will significantly improve the efficiency of current immunotherapies and set the stage for a future phase I/II clinical trial to develop more effective combinatorial therapies for refractory head and neck cancer patients. Importantly, my findings could also be translated into the treatment of other related types of immune "cold" cancers.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
454774
Name
Zhou Shufeng
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Epigenetic control of anti-tumor immunity in squamous cell carcinoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Chromatin Accessibility; Chromatin Remodeler; Epigenetics; Head And Neck Squmaous Cell Carcinoma; Immune Checkpoint Inhibitors; Immune Cold Tumors; Immunocompetent Mouse Models; Immunotherapy Resistance; Next Generation Sequencing; Tumor Microenviroment
Abstract
Head and neck squamous cell carcinoma, the sixth most common cancer worldwide, is a lethal malignancy. Immunotherapy is a new cancer treatment that aims to stimulate our immune system to fight such refractory cancers more effectively. Unfortunately, only less than 20% of head and neck cancer patients respond to this treatment. The majority of head and neck cancers are immune "cold" tumors because they lack tumor infiltrating immune cells that can kill cancer cells. These immune "cold" tumors are resistant to immunotherapy and are associated with poor prognosis. Moreover, there are no established biomarkers to discern which patients are more likely to benefit from immunotherapies. To reduce mortality of head and neck cancer patients, we therefore need to understand how cancer cells become resistant to immunotherapies and to develop biomarkers to predict patients' response to such therapies. This would allow us to develop better combinatorial strategies to improve the efficacy of cancer immune therapies. Recently, our laboratory has discovered a previously unknown mechanism by which such cancers avoid immune cell attack and develop resistance to immunotherapy. My project aims to understand how this mechanism drives tumors to develop therapeutic resistance. Understanding this will allow us to reverse this tumor survival mechanism and develop combinatorial therapies to improve the efficacy of the current immune therapies. Finally, I also aim to identify biomarkers to predict patients' response to immunotherapies. Findings from this research will significantly improve the efficiency of current immunotherapies and set the stage for a future phase I/II clinical trial to develop more effective combinatorial therapies for refractory head and neck cancer patients. Importantly, my findings could also be translated into the treatment of other related types of immune "cold" cancers.
Competitiondate
202110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Zhou, Shufeng
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~